Redsense Medical receives market approval in Singapore

Redsense Medical has received market approval for its blood loss alarm in Singapore. An order from the company’s distributor Transmedic is expected in Q3 2018 for the planned evaluation at Singapore General Hospital.

The application for a market approval was filed earlier in 2018, when Redsense Medical signed a distributor agreement for Singapore with the company Transmedic. 

The evaluation at Singapore General Hospital was initially expected to be initiated in Q1 2018. It was however stated at the time it could not be started until a market approval was received.

Singapore is an important Asian market with more than 120 dialysis centers. They cover over 7 000 patients of which 87 percent receive hemodialys treatments. 

For more information, please contact
Patrik Byhmer, CEO Redsense Medical AB (publ)
Telephone: +46 (0) 35 - 10 60 30
Email: patrik.byhmer@redsensemedical.com
Website: www.redsensemedical.com

About Redsense Medical

Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense system, a medical technology product used for monitoring and alarm in the case of blood leakage in connection with hemodialysis. Redsense solves one of the most serious remaining safety problems within hemodialysis – to quickly detect venous needle dislodgement and catheter leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector.

This information is such information that Redsense Medical AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the above contact, for publication on the 29th of May 2018.